175 related articles for article (PubMed ID: 33086530)
1. Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer.
Cimas FJ; Niza E; Juan A; Noblejas-López MDM; Bravo I; Lara-Sanchez A; Alonso-Moreno C; Ocaña A
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33086530
[TBL] [Abstract][Full Text] [Related]
2. MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
Noblejas-López MDM; Nieto-Jiménez C; Galán-Moya EM; Tebar-García D; Montero JC; Pandiella A; Burgos M; Ocaña A
J Exp Clin Cancer Res; 2021 Mar; 40(1):106. PubMed ID: 33741018
[TBL] [Abstract][Full Text] [Related]
3. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the Kinetic Characteristics and Degradation Preference of PROTAC Systems with Advanced Theoretical Analyses.
Tang R; Wang Z; Xiang S; Wang L; Yu Y; Wang Q; Deng Q; Hou T; Sun H
JACS Au; 2023 Jun; 3(6):1775-1789. PubMed ID: 37388700
[TBL] [Abstract][Full Text] [Related]
5. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Tarantelli C; Cannas E; Ekeh H; Moscatello C; Gaudio E; Cascione L; Napoli S; Rech C; Testa A; Maniaci C; Rinaldi A; Zucca E; Stathis A; Ciulli A; Bertoni F
Explor Target Antitumor Ther; 2021; 2(6):586-601. PubMed ID: 36046113
[TBL] [Abstract][Full Text] [Related]
6. BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines.
Lang C; Stickler S; Rath B; Teufelsbauer M; Weigl L; Hohenegger M; Hamilton G
Anticancer Res; 2024 Mar; 44(3):971-980. PubMed ID: 38423674
[TBL] [Abstract][Full Text] [Related]
7. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract][Full Text] [Related]
8. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
9. Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells.
Zhang H; Li G; Zhang Y; Shi J; Yan B; Tang H; Chen S; Zhang J; Wen P; Wang Z; Pang C; Li J; Guo W; Zhang S
Front Oncol; 2019; 9():1471. PubMed ID: 31993368
[No Abstract] [Full Text] [Related]
10. Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation.
Huang Y; Yokoe H; Kaiho-Soma A; Takahashi K; Hirasawa Y; Morita H; Ohtake F; Kanoh N
Bioconjug Chem; 2022 Jan; 33(1):142-151. PubMed ID: 34878263
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.
Juan A; Noblejas-López MDM; Bravo I; Arenas-Moreira M; Blasco-Navarro C; Clemente-Casares P; Lara-Sánchez A; Pandiella A; Alonso-Moreno C; Ocaña A
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139634
[TBL] [Abstract][Full Text] [Related]
12. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
[TBL] [Abstract][Full Text] [Related]
13. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of a Macrocyclic PROTAC.
Testa A; Hughes SJ; Lucas X; Wright JE; Ciulli A
Angew Chem Int Ed Engl; 2020 Jan; 59(4):1727-1734. PubMed ID: 31746102
[TBL] [Abstract][Full Text] [Related]
15. General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex.
Lin W; Chen T
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):941-952. PubMed ID: 33860212
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy.
Huang J; Yao Z; Li B; Ping Y
J Control Release; 2023 Sep; 361():270-279. PubMed ID: 37541594
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
Yang CY; Qin C; Bai L; Wang S
Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]